/TRML
TRML Stock - Tourmaline Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$47.98+0.00%
+$0.00 (+0.00%) • Oct 28
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).47
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-1.3%upside
Target: $47.36
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TRML
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$47.50 – $48.46
TARGET (TP)$47.36
STOP LOSS$44.14
RISK/REWARD1:-0.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.58
52W High$48.27
52W Low$11.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-39,000 | $-33,000 | $-6,000 | $-623,000 | $-447,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-89,732,000 | $-45,409,000 | $-19,701,000 | $-47,507,000 | $-22,684,000 |
| Net Income | $-73,210,000 | $-42,124,000 | $-19,701,000 | $-904 | $-22,707,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.89 | $-8.87 | $-0.97 | $-0.00 | $-33.97 |
Company Overview
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish0 Neutral/Bearish
Price Targets
$51
Average Target
↑ 6.1% Upside
Now
$41
Low
$51
Average
$70
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 23rd 2025 | Chardan Capital Markets | Initiation | Buy | $70 |
| March 6th 2025 | Wedbush | Initiation | Outperform | $42 |
| December 6th 2024 | BMO Capital Markets | Initiation | Outperform | $50 |
| November 11th 2024 | H.C. Wainwright | Reiterated | Buy | $49← $48 |
| December 15th 2023 | Jefferies | Initiation | Buy | $41 |
| December 4th 2023 | H.C. Wainwright | Resumed | Buy | $48 |
| November 17th 2023 | Truist | Initiation | Buy | $43 |
| October 31st 2023 | Guggenheim | Initiation | Buy | $50 |
| October 25th 2023 | Piper Sandler | Initiation | Overweight | $65 |
Earnings History & Surprises
TRMLBeat Rate
85%
Last 13 quarters
Avg Surprise
+27.7%
EPS vs Estimate
Beats / Misses
11/2
Last 12 quarters
Latest EPS
$-0.78
Q4 2025
EPS Surprise History
Q1 24
-8.0%
$-0.81vs$-0.75
Q2 24
+19.1%
$-0.55vs$-0.68
Q3 24
+5.6%
$-0.68vs$-0.72
Q4 24
+7.1%
$-0.78vs$-0.84
Q1 25
+5.5%
$-0.86vs$-0.91
Q2 25
+2.2%
$-0.89vs$-0.91
Q3 25
+4.3%
$-0.90vs$-0.94
Q4 25
+18.7%
$-0.78vs$-0.96
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 6, 2025 | $-0.96 | $-0.78 | +18.7% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.94 | $-0.90 | +4.3% | ✓ BEAT |
Q2 2025 | May 2, 2025 | $-0.91 | $-0.89 | +2.2% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.91 | $-0.86 | +5.5% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.84 | $-0.78 | +7.1% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.72 | $-0.68 | +5.6% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.68 | $-0.55 | +19.1% | ✓ BEAT |
Q1 2024 | Mar 19, 2024 | $-0.75 | $-0.81 | -8.0% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.94 | $-1.64 | -74.5% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-2.00 | $-0.20 | +90.0% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-3.87 | $-0.37 | +90.5% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q3 2022 | Sep 30, 2022 | $-4.54 | $-0.00 | +100.0% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-4.55 | $-0.00 | +100.0% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-3.48 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-3.18 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-4.15 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-2.43 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-9.60 | — | — |
Latest News
Cantor Fitzgerald Suspends Overweight Rating on Tourmaline Bio
📉 NegativeBenzinga•Oct 29, 2025, 01:54 PM
BMO Capital Downgrades Tourmaline Bio to Market Perform, Raises Price Target to $48
➖ NeutralBenzinga•Sep 15, 2025, 10:16 AM
Piper Sandler Downgrades Tourmaline Bio to Neutral, Lowers Price Target to $48
📉 NegativeBenzinga•Sep 11, 2025, 06:20 PM
Truist Securities Downgrades Tourmaline Bio to Hold, Lowers Price Target to $48
📉 NegativeBenzinga•Sep 10, 2025, 01:15 PM
Guggenheim Downgrades Tourmaline Bio to Neutral, Lowers Price Target to $48
➖ NeutralBenzinga•Sep 10, 2025, 12:46 PM
HC Wainwright & Co. Downgrades Tourmaline Bio to Neutral, Lowers Price Target to $48
📉 NegativeBenzinga•Sep 10, 2025, 11:00 AM
Chardan Capital Downgrades Tourmaline Bio to Neutral, Lowers Price Target to $48
➖ NeutralBenzinga•Sep 10, 2025, 10:21 AM
LifeSci Capital Downgrades Tourmaline Bio to Market Perform, Announces $48 Price Target
➖ NeutralBenzinga•Sep 9, 2025, 07:53 PM
Jefferies Downgrades Tourmaline Bio to Hold, Lowers Price Target to $47.5
📉 NegativeBenzinga•Sep 9, 2025, 07:36 PM
Wedbush Downgrades Tourmaline Bio to Neutral, Maintains Price Target to $48
➖ NeutralBenzinga•Sep 9, 2025, 12:28 PM
Novartis Agrees To Acquire Tourmaline Bio For $48 Per Share At Approximately $1.4B On Fully Diluted Basis
📈 PositiveBenzinga•Sep 9, 2025, 09:29 AM•Also:
Reported Sunday, Tourmaline Bio Presents TRANQUILITY Phase 2 Data Showing Pacibekitug Achieves Consistent hs-CRP Reductions Across Clinically Meaningful Subgroups
📈 PositiveBenzinga•Sep 2, 2025, 07:40 AM
Tourmaline Bio Reports Loss as R&D Rises
📉 NegativeThe Motley Fool•Aug 13, 2025, 11:26 AM
Frequently Asked Questions about TRML
What is TRML's current stock price?
Tourmaline Bio, Inc. (TRML) is currently trading at $47.98 per share. The stock has moved +0.00% today.
What is the analyst price target for TRML?
The average analyst price target for TRML is $47.36, based on 1 analyst.
What sector is Tourmaline Bio, Inc. in?
Tourmaline Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TRML's market cap?
Tourmaline Bio, Inc. has a market capitalization of $1.23 billion, making it a small-cap company.
Does TRML pay dividends?
No, Tourmaline Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMLX
Amylyx Pharmaceuticals, Inc.
$12.02
Mkt Cap: $1.0B
DNTH
Dianthus Therapeutics, Inc.
$42.44
Mkt Cap: $1.5B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
PGEN
Precigen, Inc.
$4.32
Mkt Cap: $1.3B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
TERN
Terns Pharmaceuticals, Inc.
$39.90
Mkt Cap: $3.6B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
Explore stocks similar to TRML for comparison